Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 10 | 2024 | 328 | 3.320 |
Why?
|
| Critical Illness | 8 | 2023 | 141 | 3.190 |
Why?
|
| Sepsis | 7 | 2020 | 153 | 2.780 |
Why?
|
| Critical Care | 7 | 2024 | 246 | 2.560 |
Why?
|
| Physicians | 3 | 2021 | 119 | 1.930 |
Why?
|
| Family | 4 | 2024 | 100 | 1.700 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 50 | 1.140 |
Why?
|
| Hospital Mortality | 3 | 2020 | 150 | 1.120 |
Why?
|
| Staphylococcal Infections | 5 | 2020 | 185 | 1.110 |
Why?
|
| Anxiety | 3 | 2023 | 156 | 1.060 |
Why?
|
| Neoplasms | 2 | 2020 | 261 | 0.990 |
Why?
|
| Depression | 3 | 2023 | 481 | 0.860 |
Why?
|
| Communication | 2 | 2023 | 120 | 0.820 |
Why?
|
| Stress, Psychological | 2 | 2021 | 254 | 0.780 |
Why?
|
| Palliative Medicine | 1 | 2021 | 10 | 0.780 |
Why?
|
| Bacteremia | 4 | 2020 | 119 | 0.770 |
Why?
|
| Humans | 25 | 2024 | 31036 | 0.760 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 88 | 0.750 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 199 | 0.720 |
Why?
|
| Adult | 13 | 2022 | 8944 | 0.690 |
Why?
|
| Patient Advocacy | 1 | 2019 | 15 | 0.680 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 19 | 0.680 |
Why?
|
| Tracheostomy | 1 | 2018 | 25 | 0.640 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 5 | 0.630 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 6 | 0.630 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 37 | 0.620 |
Why?
|
| Patient Care Team | 1 | 2019 | 152 | 0.590 |
Why?
|
| Chronic Disease | 1 | 2019 | 534 | 0.580 |
Why?
|
| HIV Infections | 2 | 2016 | 886 | 0.560 |
Why?
|
| Middle Aged | 13 | 2021 | 10221 | 0.550 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 8 | 0.550 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 10 | 0.530 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 117 | 0.500 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 56 | 0.500 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 139 | 0.490 |
Why?
|
| Decision Making | 3 | 2021 | 236 | 0.470 |
Why?
|
| Immune System Diseases | 1 | 2014 | 1 | 0.470 |
Why?
|
| Aged | 11 | 2021 | 10063 | 0.460 |
Why?
|
| Male | 13 | 2021 | 16478 | 0.440 |
Why?
|
| Algorithms | 1 | 2016 | 416 | 0.440 |
Why?
|
| Female | 13 | 2021 | 16983 | 0.430 |
Why?
|
| Pandemics | 2 | 2021 | 274 | 0.320 |
Why?
|
| Cross Infection | 1 | 2011 | 309 | 0.320 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3663 | 0.320 |
Why?
|
| Cytokines | 3 | 2020 | 351 | 0.310 |
Why?
|
| Hospitalization | 3 | 2021 | 336 | 0.300 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1210 | 0.260 |
Why?
|
| Prognosis | 2 | 2020 | 923 | 0.260 |
Why?
|
| Chicago | 2 | 2019 | 938 | 0.260 |
Why?
|
| Length of Stay | 2 | 2018 | 339 | 0.250 |
Why?
|
| Influenza, Human | 2 | 2016 | 50 | 0.250 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 367 | 0.250 |
Why?
|
| Age Factors | 2 | 2018 | 872 | 0.240 |
Why?
|
| Policy | 1 | 2023 | 11 | 0.220 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1134 | 0.220 |
Why?
|
| Consensus | 1 | 2023 | 112 | 0.210 |
Why?
|
| Morals | 1 | 2021 | 13 | 0.200 |
Why?
|
| Th2 Cells | 2 | 2019 | 28 | 0.200 |
Why?
|
| Th17 Cells | 2 | 2019 | 29 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2021 | 1896 | 0.190 |
Why?
|
| Sleep | 1 | 2024 | 321 | 0.180 |
Why?
|
| Immunity | 1 | 2020 | 26 | 0.180 |
Why?
|
| Body Temperature | 1 | 2020 | 58 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 5195 | 0.180 |
Why?
|
| Uncertainty | 1 | 2020 | 8 | 0.180 |
Why?
|
| Health Personnel | 1 | 2021 | 118 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 410 | 0.170 |
Why?
|
| ROC Curve | 2 | 2018 | 145 | 0.170 |
Why?
|
| Palliative Care | 1 | 2021 | 154 | 0.170 |
Why?
|
| United States | 3 | 2021 | 2376 | 0.170 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 28 | 0.170 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 2 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 49 | 0.160 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 9 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 28 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2019 | 98 | 0.160 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 35 | 0.160 |
Why?
|
| Public Policy | 1 | 2018 | 9 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 34 | 0.150 |
Why?
|
| Social Capital | 1 | 2018 | 5 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 143 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 2580 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 48 | 0.150 |
Why?
|
| Social Class | 1 | 2018 | 68 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2018 | 204 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2018 | 293 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 333 | 0.150 |
Why?
|
| Social Environment | 1 | 2018 | 87 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2018 | 427 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 508 | 0.140 |
Why?
|
| APACHE | 1 | 2016 | 32 | 0.140 |
Why?
|
| Quality of Life | 1 | 2021 | 697 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2018 | 661 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2016 | 16 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2018 | 224 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2018 | 145 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 447 | 0.130 |
Why?
|
| Coinfection | 1 | 2016 | 30 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 23 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2016 | 39 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2016 | 71 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 20 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2016 | 353 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1678 | 0.120 |
Why?
|
| Antioxidant Response Elements | 1 | 2013 | 1 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 2 | 0.110 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 22 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2013 | 134 | 0.100 |
Why?
|
| Georgia | 1 | 2011 | 12 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 130 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 82 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 232 | 0.090 |
Why?
|
| HIV-1 | 1 | 2013 | 456 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 571 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2016 | 686 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2016 | 635 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3807 | 0.050 |
Why?
|
| Child | 2 | 2016 | 1428 | 0.050 |
Why?
|
| Fever | 1 | 2020 | 42 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2020 | 67 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 2400 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2057 | 0.040 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2019 | 2 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 21 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 10 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2019 | 47 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 120 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 323 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 173 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 464 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 4713 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 408 | 0.040 |
Why?
|
| Asthma | 1 | 2019 | 139 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 586 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 782 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 15 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 322 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 95 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 165 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 135 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 507 | 0.030 |
Why?
|
| Quinones | 1 | 2013 | 1 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2013 | 6 | 0.030 |
Why?
|
| Thiocyanates | 1 | 2013 | 3 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2013 | 5 | 0.030 |
Why?
|
| Claudins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2013 | 18 | 0.030 |
Why?
|
| Occludin | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutathione | 1 | 2013 | 32 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 16 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2013 | 21 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 783 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 34 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 114 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2040 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2013 | 329 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2013 | 686 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 870 | 0.020 |
Why?
|